I am very involved in clinical trials, particularly those of targeted drugs known as kinase inhibitors, which block pathways inside cancer cells that cause the cells to grow or spread. One area of focus in my research is studying patients who are known as extraordinary responders. These are people with difficult-to-treat cancers who are found to respond exceptionally well to a new drug, even though that drug does not work in most people with the same disease.